Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03567642 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03567642 · ClinicalTrials.gov record · last posted 2026-07-06

A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

Name: A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers — clinical trial record (NCT03567642)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorMemorial Sloan Kettering Cancer Center

Started2018-06-12

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to test the safety of combining Osimertinib with either Cisplatin or Carboplatin (at different dose levels) and Etoposide, to find out what effects, if any, this combination of drugs has on people with EGFR mutant lung cancer.

Amendment record 14 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 14 times since 2018-06-13; most recent amendment 2026-07-01. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-02-12

Status change Recruiting→Active, Not Recruitingv11

Trial Details

NCT Number	NCT03567642
Lead Sponsor	Memorial Sloan Kettering Cancer Center
Conditions	Lung Cancer
Enrollment	11 participants
Start Date	2018-06-12
Primary Completion	2027-06 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-06